ライフサイエンスコーパス: T-cell immunity

1 regnancy is associated with recovery of CD4+ T cell immunity.

2 tages of tumor inception to subvert adaptive T cell immunity.

3 ection of human DCs compromises WNV-specific T cell immunity.

4 ans are an essential component of long-lived T cell immunity.

5 M) subsets that likely compromise anti-tumor T cell immunity.

6 ificant impact on HPV-specific CD8+ and CD4+ T cell immunity.

7 heir JAK/STAT pathways play pivotal roles in T cell immunity.

8 lls but did not explain the defect in CD8(+) T cell immunity.

9 re critical for the generation of protective T cell immunity.

10 aneous and PD-L1-blockade-mediated antitumor T cell immunity.

11 duction of IL-1beta, and defective antiviral T cell immunity.

12 or the generation of an optimal effector CD8 T cell immunity.

13 sepsis might facilitate the recovery of CD8 T cell immunity.

14 and inhibits formation of pathogen-specific T cell immunity.

15 ex class II expression, suggesting a role in T cell immunity.

16 tifiers to explore the long-term dynamics of T cell immunity.

17 e immunogenicity for inducing antibodies and T cell immunity.

18 function of FcgammaRIIB in regulating CD8(+) T cell immunity.

19 e development of vaccines that evoke optimal T cell immunity.

20 and qualitatively altered YF-specific CD4(+) T cell immunity.

21 studies unveil an essential role of Gpx4 for T cell immunity.

22 specific subsets of dendritic cells and CD8 T cell immunity.

23 ant peptide is virtually unable to stimulate T cell immunity.

24 re characterized by their ability to inhibit T cell immunity.

25 d tissue in part by evading antiviral CD8(+) T cell immunity.

26 overlapping and yet distinct mucosal and DC/T cell immunity.

27 are considered to play little or no role in T cell immunity.

28 a broad spectrum of biological processes of T cell immunity.

29 formation of resident versus nonresident CD8 T cell immunity.

30 T cells into strategies designed to enhance T cell immunity.

31 esentation by pDCs in driving proatherogenic T cell immunity.

32 hat endogenous GCs both promote and suppress T cell immunity.

33 f NPs to distinct DC subsets led to enhanced T cell immunity.

34 which is critically dependent on Ag-specific T cell immunity.

35 monstrate the role of FA synthesis in CD8(+) T cell immunity.

36 tudies of the role of RAR isoforms in CD8(+) T cell immunity.

37 of the host to mount effective antiviral CD8 T cell immunity.

38 immune tolerance and tips the balance toward T cell immunity.

39 nd IL-2 production to facilitate optimal CD8 T cell immunity.

40 ly employed cytokines; and (4) activators of T cell immunity.

41 led to low expression of STAT5 and impaired T cell immunity.

42 Adaptive evolution is a key feature of T cell immunity.

43 pathogenesis, but few studies have evaluated T cell immunity.

44 iral persistence associates with compromised T cell immunity.

45 lular source, and timing of Notch signals in T cell immunity.

46 led to strong cross-priming and durable CD8 T cell immunity.

47 therapy associated with enhanced anti-tumor T cell immunity.

48 heckpoint that is crucial for the control of T cell immunity.

49 y systemic poly-functional CD4(+) and CD8(+) T cell immunity.

50 ptake deficiency severely impaired antitumor T cell immunity.

51 ation, and ablation of FGL1 in mice promotes T cell immunity.

52 L1 and exploit PD-L1/PD-1 signaling to evade T cell immunity.

53 ove rather than compromise protective CD8(+) T cell immunity.

54 (AHR) in TAMs to modulate their function and T cell immunity.

55 lied partly on induction of sustainable host T-cell immunity.

56 nts in nanoparticles for inducing anticancer T-cell immunity.

57 and "atypical" SCID show reduced, not absent T-cell immunity.

58 for sterols and oxysterols in macrophage and T-cell immunity.

59 igen-presenting cells to stimulate antitumor T-cell immunity.

60 was associated with enhanced virus-specific T-cell immunity.

61 DTP on innate proinflammatory responses and T-cell immunity.

62 ls, suggesting interference of carriage with T-cell immunity.

63 hanism involving the inhibition of antitumor T-cell immunity.

64 aling as a viable approach to augment CD8(+) T-cell immunity.

65 ler (NK) cells, macrophage polarization, and T-cell immunity.

66 ory bowel disease-all with severely impaired T-cell immunity.

67 l inadequacy to evade HLA-A*02:01-restricted T-cell immunity.

68 2:01 molecule, and play an important role in T-cell immunity.

69 e immunoregulatory cytokine IL-10 suppresses T-cell immunity.

70 e of Th17 cells to preserve an effective HIV T-cell immunity.

71 e survival by inducing robust tumor-specific T-cell immunity.

72 cal strategy to harness endogenous antitumor T-cell immunity.

73 rism with superior long-term recovery of CD4 T-cell immunity.

74 nation immunotherapies that can fully engage T-cell immunity.

75 ibody responses, we found key differences in T-cell immunity.

76 vival is dependent on their ability to evade T-cell immunity.

77 ocols to establish lifelong antigen-specific T-cell immunity.

78 uitment, which is crucial for suppression of T-cell immunity.

79 duced on activated T cells, is important for T-cell immunity.

80 ion of antigen-presenting cells that promote T-cell immunity.

81 biochemical information and are critical for T-cell immunity.

82 ce for the upregulation of genes involved in T-cell immunity.

83 t facilitates the emergence of potent CD8(+) T-cell immunity able to durably suppress virus replicati

84 in single lymphoma nodes, mediated systemic T-cell immunity accompanied by regression of disseminate

85 etween DC dysfunction and impairments in CD8 T cell immunity after sepsis by directly targeting Ag to

86 Quantifying CMV-specific T-cell immunity after HSCT can identify participants at

87 ll help to further characterize MuV-specific T-cell immunity after natural MuV infection or vaccinati

88 Here we show that T cell immunity against commensal papillomaviruses suppr

89 its potential for triggering protective CD8 T cell immunity against heterologous influenza virus cha

90 mph nodes to program DCs to direct effective T cell immunity against IAV.

91 ng evidences support a critical role of CD8+ T cell immunity against influenza.

92 ispensable for establishing effective CD4(+) T cell immunity against malaria, because it not only inh

93 onal strategies for generating heterogeneous T-cell immunity against cancer, with the appropriate bal

94 We previously described CD4(+) T-cell immunity against HBsAg and polymerase in chimpanz

95 ing cell motility are essential for adaptive T-cell immunity against infectious pathogens and cancers

96 ng evidence supports a critical role of CD8+ T-cell immunity against influenza.

97 T-cell immunity against stem-cell antigen SOX2 and prese

98 PD-L1 expression in tumour cells to enhance T-cell immunity against the tumours.

99 cells improves spontaneous antitumor CD8(+) T cell immunity and boosts the efficacy of T cell-based

100 whether, and how, ferroptosis is involved in T cell immunity and cancer immunotherapy.

101 IL-7 is a key factor in T cell immunity and common variants at IL7R, encoding it

102 nse was partially mediated by tumor-specific T cell immunity and immunological memory.

103 e acute stages of sepsis develop compromised T cell immunity and increased susceptibility to infectio

104 between amino acid metabolism, and effective T cell immunity and its relevance in cancer therapies.

105 rs to be a crucial component of EBV-specific T cell immunity and more generally for the immune survei

106 he key discoveries in the area of flavivirus T cell immunity and postulate on how these findings can

107 expressing macrophages that inhibited CD8(+) T cell immunity and promoted CD4(+)Foxp3(+) Treg cell ex

108 inosinic-polycytidylic acid (poly IC) on CD8 T cell immunity and protection elicited by LAIVs.

109 the complex regulatory mechanisms governing T cell immunity and regulation of a critical T cell chec

110 f there is a correlate of protection between T cell immunity and Shingrix efficacy.

111 ponses results in significant alterations in T cell immunity and subsequent disease outcome upon reex

112 lized antigen-presenting cells that initiate T cell immunity and tolerance.

113 g) are critical in the maintenance of normal T cell immunity and tolerance.

114 Thus, both T cell immunity and trypanocidal pharmacotherapy suppres

115 Normal VZV-specific T-cell immunity and antibody response were detected.

116 s recently been shown to correlate with anti T-cell immunity and efficacy of checkpoint inhibitor the

117 ve the current understanding of HIV-specific T-cell immunity and identify cellular immune responses a

118 ng phase augmented DC vaccine-induced CD8(+) T-cell immunity and improved antitumor efficacy, suggest

119 Here, CD8+ T-cell immunity and response to reinfection were assesse

120 iraemia, which leads to the establishment of T-cell immunity and resultant long-term infection contro

121 inib destabilizes PD-L1, enhances antitumour T-cell immunity and therapeutic efficacy of PD-1 blockad

122 B1 allele predicted resurgent virus-specific T-cell immunity and viral control at 3-mo postpartum (P

123 acute infectious agents induce strong CD8(+) T cell immunity, and are thought to therefore represent

124 D69 receptor, a regulator of Th17/regulatory T cell immunity, and atherosclerosis development in anim

125 d for FcgammaRIIB-mediated control of CD8(+) T cell immunity, and instead, the immunosuppressive cyto

126 dominant mechanism for regionalizing CD4(+) T cell immunity, and location enforces shared transcript

127 s contributes to the observed defects in CD8 T cell immunity, and therapeutic approaches designed to

128 otential of MDSC, triggered antitumor CD8(+) T-cell immunity, and boosted the efficacy of T-cell immu

129 hole-exome sequencing (WES), analyses of VZV T-cell immunity, and pathogen recognition receptor funct

130 rive Th17 polarization and influence mucosal T-cell immunity, and suggest that host pathways to handl

131 , viral load, the assessment of CMV-specific T-cell immunity, and the molecular assessment of resista

132 the tumor microenvironment controls TAMs and T cell immunity are not completely understood.

133 or (TNFR)-associated factor (TRAF) family in T cell immunity are not well understood.

134 H) and the resultant neoantigen landscape on T cell immunity are poorly understood.

135 e protective and pathogenic roles of GITR in T cell immunity are well characterized, the role of GITR

136 The study of T cell immunity at barrier surfaces has largely focused

137 94 HSCT recipients we evaluated CMV-specific T-cell immunity at baseline, 3, 6, 9, and 12 months afte

138 ease among those infected, but the impact of T-cell immunity at the population level is unknown.

139 , due to cross-reactive humoral immunity and T cell immunity between common coronaviruses and SARS-Co

140 tress can have long-term consequences on CD8 T cell immunity by altering HPA axis activity.

141 Reactivation of T cell immunity by PD-1/PD-L1 immune checkpoint blockade

142 Our results show that HIV-1-specific T-cell immunity can be detected in exposed but uninfecte

143 Because T-cell immunity contributes to the control of many viral

144 d to successful and sustained restoration of T-cell immunity correlated with virologic response and p

145 des from HPV-16 E6/E7 for which induction of T-cell immunity correlates with disease-free survival in

146 w evidence that stimulating effective CD8(+) T cell immunity could provide protection, and in this Pe

147 The fidelity of T cell immunity depends greatly on coupling T cell recep

148 /-) mice were deficient in generating CD8(+) T-cell immunity despite normal clonal expansion, likely

149 T cell immunity directed against tumor-encoded amino aci

150 ding imply that exosomes function to promote T cell immunity during a bacterial infection and are an

151 fundamental role in the induction of CD8(+) T cell immunity during viral, intracellular bacterial, a

152 eal a mechanism by which S. Typhi may target T-cell immunity during establishment of typhoid.

153 this study, we analyzed the role of IAPs in T-cell immunity during lymphocytic choriomeningitis viru

154 Thus, maternal CD4(+) T-cell immunity during primary rhCMV infection is import

155 dendritic cells, preeminent inducers of CD8 T cell immunity; elicit Th1-promoting inflammation; and

156 nocytogenes (which induces CD4(+) and CD8(+) T-cell immunity) engineered to express Kras(G12D) (LM-Kr

157 denoviral vectored vaccines fails to restore T-cell immunity except where there is genetic mismatch b

158 incident with development of strain-specific T-cell immunity followed by emergence of cross-reactive

159 The longitudinal development of the adaptive T cell immunity following immunization with Ag is identi

160 le test to identify recovery of CMV-specific T-cell immunity following hematopoietic stem cell transp

161 s have been a central methodology to measure T cell immunity for many years.

162 ld great promise to produce antigen-specific T cell immunity for personalized therapy of cancer.

163 Thus, CD8(+) T cell immunity generated during primary DENV infection

164 Restoration of antigen-specific T cell immunity has the potential to clear persistent vi

165 T-cell immunity has been linked to the exceptional outco

166 e metabolic regulators controlling antitumor T cell immunity have just begun to be unveiled.

167 bodies (mAbs) able to reinvigorate antitumor T-cell immunity have heralded a paradigm shift in cancer

168 should be targeted for optimal activation of T cell immunity, however, remains unknown.

169 current helminth infection potently inhibits T cell immunity; however, whether helminthes prevent T c

170 ndritic cells (cDC1s) for inducing antitumor T-cell immunity; however, strategies to maximize cDC1 en

171 We prospectively analyzed antigen-specific B/T-cell immunity, immune composition of the tumor microen

172 -associated tissue in part by evading CD8(+) T cell immunity.IMPORTANCE CHIKV is a reemerging mosquit

173 vation to compromise priming of WNV-specific T cell immunity.IMPORTANCE West Nile virus (WNV) is an e

174 While T cell immunity in brucellosis has been extensively stud

175 of these DC subsets to boost tumor-reactive T cell immunity in cancer patients.

176 ptor (TCR) gene therapy can reconstitute CD8 T cell immunity in chronic patients.

177 ese results suggest the critical role of CD4 T cell immunity in controlling varicella virus latency.

178 eactivation suggests a critical role for CD4 T cell immunity in controlling varicella virus latency.I

179 may thus be beneficial for optimizing CD8(+) T cell immunity in COVID-19.

180 ch there has been debate about centrality of T cell immunity in defense, these observations support a

181 d understanding the correlates of protective T cell immunity in HIV infection, the optimal approach t

182 ria, due to their ability to potently induce T cell immunity in humans.

183 A class II heterodimers and stimulate strong T cell immunity in mice and humans.

184 define antigenic epitopes determining CD8(+) T cell immunity in murine models of ZIKV infection.

185 However, spontaneous antitumor CD8+ T cell immunity in peripheral blood and tumors was restr

186 display diminished capacity for controlling T cell immunity in prostate inflammation and cancer mode

187 To assess the role of CD4 T cell immunity in reactivation, monkeys were treated wi

188 ontributing factor leading to diminished CD8 T cell immunity in septic hosts.

189 nterest to understand if there is a role for T cell immunity in the differential clinical outcome and

190 s for vaccines and/or therapies that require T cell immunity in the lung.

191 We also report pre-existing human CD8+T cell immunity in the majority of healthy individuals s

192 r (TSLPR), yet a direct role for TSLP in CD8 T cell immunity in the mucosa has not been described.

193 ion of TSLP levels may promote long-term CD8 T cell immunity in the mucosa when other prosurvival sig

194 methionine metabolism, histone patterns, and T cell immunity in the tumour microenvironment.

195 BACKGROUNDImpaired T cell immunity in transplant recipients is associated w

196 cells, and this was accompanied by increased T cell immunity in tumour-bearing mice and patients with

197 evaluated peripheral blood and lung mucosal T-cell immunity in 14 HIV(+)COPD(+), 13 HIV(+)COPD(-), a

198 is therefore a novel functional component of T-cell immunity in latent TB and potential correlate of

199 nd DNA sequencing, and assessed CMV-specific T-cell immunity in LTRs at high risk for CMV events, usi

200 nfections support the clinical importance of T-cell immunity in mediating protective antiviral effect

201 results suggest that IL-10 suppresses CD4(+) T-cell immunity in nonvaccinated mice during Coccidioide

202 -alpha therapy fails to boost virus-specific T-cell immunity in patients with chronic hepatitis B vir

203 This investigation of virus-specific T-cell immunity in patients with HDV infection, the larg

204 eptor and the cytokine IL-2, but its role in T-cell immunity in vivo has not been explored.

205 perimentation to better understand antiviral T-cell immunity in vivo Limiting factors in ACT experime

206 o be of significant importance in regulating T-cell immunity in vivo.

207 odeficiencies are marked by inborn errors of T-cell immunity in which the T cells that are present ar

208 tegies, the therapeutic goal is to re-ignite T-cell immunity, in order to eradicate tumors.

209 ere we discuss new approaches to probe human T cell immunity, including novel sampling, that indicate

210 Identification of positive regulators of T-cell immunity induced during autoimmune diseases is cr

211 the efficient induction of stable antiviral T cell immunity irrespective of the nature of the antige

212 Generating effective and durable T cell immunity is a critical prerequisite for vaccinati

213 ses (IAVs), where the recall of IAV-specific T cell immunity is able to protect against serologically

214 Reconstitution of T cell immunity is absolutely critical for the effective

215 Induction of proinflammatory T cell immunity is augmented by innate dendritic cell (D

216 articular, IFN-gamma-polarized cytotoxic CD8 T cell immunity is considered optimal for protective imm

217 T cell immunity is essential for the control of cytomega

218 e minimal thresholds for effective antiviral T cell immunity is important for clinical decisions in i

219 ection against reinfection and that adaptive T cell immunity is important for viral clearance.

220 eatment for malaria and other diseases where T cell immunity is ineffective or short-lived due to PD-

221 T cell immunity is often defined in terms of memory lymp

222 Optimal CD8 T cell immunity is orchestrated by signaling events init

223 ivery of IL-1beta to determine that adaptive T cell immunity is required for airway remodeling becaus

224 of IFN-gamma in tuberculosis (TB), and CD4+ T cell immunity is the main target of current TB vaccine

225 T cell immunity is vital for the control of KSHV infecti

226 T-cell immunity is critical for control of CMV infection

227 An important question is whether T-cell immunity is sufficiently strong to drive influenz

228 Thus, eliciting robust CD8 T-cell immunity is the basis for many vaccines under dev

229 Adaptive CD8 T-cell immunity is the principal arm of the cellular all

230 c cell antigen presentation, but its role in T-cell immunity is unknown.

231 A characterization of RSV-specific T-cell immunity is warranted.

232 mokine pathway is critical in shaping CD8(+) T cell immunity, locally within latently infected tissue

233 s, but it is unknown whether disturbances to T cell immunity may render these patients vulnerable to

234 the notable implication that restoring CD4+ T cell immunity might contribute to controlling HCV infe

235 T-cell immunity might be an essential component of safe,

236 enhanced dengue infections suggest that poor T-cell immunity might have contributed to protection fai

237 n of whether preexisting dengue virus (DENV) T cell immunity modulates these responses.

238 NV cross-reactivity and how preexisting DENV T cell immunity modulates Zika T cell responses is of gr

239 ts, we evaluated the contributions to CD8(+) T cell immunity of CD40 expressed on host tissues includ

240 ime a dual impact of host adaptive antitumor T-cell immunity on the clinical effectiveness of rapalog

241 have generally focused on either stimulating T cell immunity or driving antibody-directed effector fu

242 duction, pDCs can also process Ag and induce T cell immunity or tolerance.

243 his study, we sought to investigate the role T cell immunity plays in recognizing and controlling gen

244 Naturally occurring cross-protective T-cell immunity protects against symptomatic PCR-confirm

245 EPO-R signaling on T cells to inhibition of T-cell immunity, providing one mechanism that could expl

246 the molecular mechanisms of vaccine-elicited T cell immunity remains a critical knowledge gap in vacc

247 directly affect cancer immune phenotype and T cell immunity remains a standing question.

248 endritic cells (DCs) in priming WNV-specific T cell immunity remains poorly understood.

249 However, the influence of SOR on T cell immunity remains uncharacterized.

250 n tumor defenses and recover the preexisting T-cell immunity required to respond to immunotherapy.

251 T-cell immunity requires extremely rapid clonal prolifer

252 However, current LAIVs exert limited T cell immunity restricted to the vaccine strains.

253 Absent T-cell immunity resulting in life-threatening infections

254 Mouse studies of T cell immunity show that, in response to infection, T c

255 of B cells in TB vaccine-induced protective T cell immunity still remains unknown.

256 e parameters of M. tuberculosis-specific CD4 T cell immunity that are impaired in HIV-infected indivi

257 s (LAIVs) have the potential to generate CD8 T cell immunity that may limit the virulence of an antig

258 Ketorolac unleashed anticancer T cell immunity that was augmented by immune checkpoint

259 te the importance of the co-receptor PD-1 in T cell immunity, the upstream signaling pathway that reg

260 further demonstrate that, unlike evasion of T cell immunity, this viral Fcgamma receptor is not requ

261 recruitment of mast cells and activation of T cell immunity through C3a are important for parasite c

262 fense, these observations support a role for T cell immunity to AhpC in disease protection.

263 Thus, long-term CD8(+) T cell immunity to chronic viral infection requires uniq

264 irus (CMV) persists in most humans, requires T cell immunity to control, yet tissue immune responses

265 T cell immunity to GroEL (BPSL2697) was specifically imp

266 epitope recognition by CD8(+)T cells, CD4(+)T cell immunity to KSHV may be important for maintaining

267 eceptor 3 (CXCR3) chemokine pathway promotes T cell immunity to many viral pathogens, but its importa

268 nal neoantigens as the basis for ineffective T cell immunity to melanoma and support the concept that

269 le for p110delta signaling in in vivo CD8(+) T cell immunity to microbial pathogens.

270 Survival was associated with enhanced T cell immunity to nine of fifteen immunodominant antige

271 endogenous NK cell and tumor Ag-specific CD8 T cell immunity to provide a marked reduction in tumor b

272 iral pathogens, but its importance in CD8(+) T cell immunity to recurrent herpes has been poorly eluc

273 ines that better recapitulate natural CD8(+) T cell immunity to SARS-CoV-2.

274 Preexisting T cell immunity to severe acute respiratory syndrome cor

275 sistance may provide insight into protective T cell immunity to TB.

276 ccines are a promising approach for inducing T cell immunity to tumor neoantigens.

277 g allogeneic pancreatic tumor cells, induces T-cell immunity to cancer antigens, including mesothelin

278 Studies of T-cell immunity to human cytomegalovirus (CMV) primarily

279 erculosis infection, and in the evolution of T-cell immunity to M. tuberculosis in response to tuberc

280 ne (LAIV) is unique in its ability to elicit T-cell immunity to the conserved internal proteins of th

281 with an imbalance of T(H)1 versus regulatory T cell immunity toward the retinal protein, recoverin.

282 enhances the human NoV-specific mucosal and T cell immunities triggered by a VSV-based human NoV vac

283 nt metabolic regulator controlling antitumor T cell immunity, underscoring the potential of creatine

284 tion; and (iv) inhibiting antitumor adaptive T cell immunity via the programmed death-1 (PD-1)-progra

285 as associated with more pronounced antitumor T-cell immunity via induction of IL17 and IFNgamma-produ

286 omain-containing molecule 4 (Tim4) regulates T-cell immunity via phagocytosis of both apoptotic (high

287 Reconstitution of CMV-specific T cell immunity was evident and CMV-specific ACT may tri

288 deficient and wild-type neutrophils, whereas T cell immunity was increased in chimeric mice with NGAL

289 ofound negative effect of IAP antagonists on T-cell immunity was partially linked to tumor necrosis f

290 genetic diagnosis nor basic measurements of T-cell immunity were good predictors of disease evolutio

291 be successfully sensitized to host antitumor T cell immunity when appropriately selected immunogenic

292 (Trib1) as a central regulator of antiviral T cell immunity, where loss of Trib1 led to a sustained

293 dendritic cells (DCs) is required to induce T cell immunity, whereas immature DCs can induce immune

294 vaccine development have focused on adaptive T cell immunity, whereas the importance of innate immune

295 ential for the initiation of adaptive CD8(+) T cell immunity, which in turn is critical for effective

296 converge on NFATc1 with opposing effects on T cell immunity, which may underlie the beneficial effec

297 um of which is necessary for preservation of T cell immunity while suppressing tissue damage.

298 atic CD4(+) T-cell compartment that suppress T-cell immunity while concomitantly promoting aberrant I

299 ovide criteria for optimizing protective CD8 T cell immunity with rAd vaccines.

300 itioning regulates the extent and quality of T cell immunity, with important implications for vaccine